PetMed Express, Inc. (NASDAQ:PETS) has been given a consensus recommendation of “Hold” by the eight analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $42.00.

A number of analysts have recently weighed in on PETS shares. Craig Hallum restated a “hold” rating and issued a $40.00 price objective (down from $43.00) on shares of PetMed Express in a research note on Monday, August 21st. They noted that the move was a valuation call. BidaskClub cut shares of PetMed Express from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 22nd. Sidoti upgraded shares of PetMed Express from a “neutral” rating to a “buy” rating and set a $47.00 price objective for the company in a research note on Thursday, August 24th. ValuEngine upgraded shares of PetMed Express from a “hold” rating to a “buy” rating in a research note on Friday, September 1st. Finally, Zacks Investment Research cut shares of PetMed Express from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 25th.

Shares of PetMed Express (PETS) opened at $39.34 on Friday. PetMed Express has a one year low of $19.21 and a one year high of $50.90. The firm has a market cap of $810.57, a price-to-earnings ratio of 26.46, a PEG ratio of 2.37 and a beta of 1.09.

PetMed Express (NASDAQ:PETS) last issued its quarterly earnings data on Monday, October 23rd. The company reported $0.43 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.30 by $0.13. PetMed Express had a net margin of 11.58% and a return on equity of 31.46%. The business had revenue of $66.70 million during the quarter, compared to analysts’ expectations of $63.41 million. During the same period in the previous year, the company earned $0.24 earnings per share. PetMed Express’s revenue for the quarter was up 9.7% on a year-over-year basis. equities research analysts forecast that PetMed Express will post 1.67 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, November 17th. Investors of record on Monday, November 6th were given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 2.03%. The ex-dividend date of this dividend was Friday, November 3rd. PetMed Express’s dividend payout ratio (DPR) is currently 53.69%.

In related news, Director Ronald J. Korn sold 1,000 shares of the business’s stock in a transaction on Friday, October 27th. The shares were sold at an average price of $35.57, for a total transaction of $35,570.00. Following the transaction, the director now owns 73,833 shares of the company’s stock, valued at $2,626,239.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.00% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Pinebridge Investments L.P. increased its position in PetMed Express by 1.0% during the second quarter. Pinebridge Investments L.P. now owns 2,704 shares of the company’s stock worth $110,000 after acquiring an additional 27 shares during the period. Acrospire Investment Management LLC bought a new stake in PetMed Express in the 2nd quarter valued at $110,000. Sei Investments Co. increased its holdings in PetMed Express by 50,142.9% in the 3rd quarter. Sei Investments Co. now owns 3,517 shares of the company’s stock valued at $117,000 after buying an additional 3,510 shares during the period. Thompson Siegel & Walmsley LLC bought a new stake in PetMed Express in the 3rd quarter valued at $149,000. Finally, Fred Alger Management Inc. bought a new stake in PetMed Express in the 2nd quarter valued at $162,000. 99.75% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “PetMed Express, Inc. (PETS) Receives Consensus Rating of “Hold” from Analysts” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/02/petmed-express-inc-pets-receives-consensus-rating-of-hold-from-analysts.html.

About PetMed Express

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Analyst Recommendations for PetMed Express (NASDAQ:PETS)

Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.